Fig. 6

‘Immune-privileged’ sites and CRISPR/Cas9-mediating gene editing. Implementing the CRISPR Cas system for gene editing early in person’s life; and targeting immune-privileged organs are all attempts to overcome the limitations provided by immunogenicity against Cas9